Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock Has Consensus Price Target of $44.25

Stoke Therapeutics, Inc. (NASDAQ:STOK) has been given a consensus rating of “Moderate Buy” by the eleven analysts that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and ten have issued a buy rating on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $44.25.

A number of equities research analysts have weighed in on the company. Guggenheim restated a “buy” rating and issued a $60.00 target price on shares of Stoke Therapeutics in a research report on Tuesday, August 4th. JPMorgan Chase & Co. initiated coverage on Stoke Therapeutics in a research report on Friday, August 21st. They set an “overweight” rating and a $40.00 price objective for the company. Wedbush boosted their target price on Stoke Therapeutics from $38.00 to $40.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. Canaccord Genuity Group cut their price objective on Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating on the stock in a report on Tuesday, August 4th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating on shares of Stoke Therapeutics in a research note on Thursday, September 10th.

Stoke Therapeutics Stock Performance

STOK stock opened at $25.04 on Friday. The stock’s fifty day moving average is $27.99 and its two-hundred day moving average is $30.31. The stock has a market capitalization of $1.62 billion, a price-to-earnings ratio of -7.50 and a beta of 1.26. Stoke Therapeutics has a 1 year low of $20.32 and a 1 year high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. The business had revenue of $9.32 million for the quarter, compared to the consensus estimate of $4.89 million. As a group, analysts predict that Stoke Therapeutics will post -3.52 EPS for the current fiscal year.

Insider Buying and Selling at Stoke Therapeutics

In other news, General Counsel Jonathan Allan sold 2,861 shares of the company’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total transaction of $91,637.83. Following the completion of the sale, the general counsel owned 21,225 shares in the company, valued at approximately $679,836.75. This represents a 11.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Barry Ticho sold 7,176 shares of the firm’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $29.04, for a total transaction of $208,391.04. Following the completion of the transaction, the insider owned 20,422 shares in the company, valued at $593,054.88. The trade was a 26.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 34,594 shares of company stock worth $1,069,305. 9.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in STOK. Bank of America Corp DE acquired a new stake in shares of Stoke Therapeutics in the 2nd quarter valued at $8,498,000. Legal & General Group Plc acquired a new stake in Stoke Therapeutics in the second quarter worth about $1,168,000. Dimensional Fund Advisors LP lifted its position in Stoke Therapeutics by 19.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 989,936 shares of the company’s stock valued at $32,229,000 after purchasing an additional 162,797 shares during the period. Janus Henderson Group PLC boosted its stake in shares of Stoke Therapeutics by 11.2% in the 1st quarter. Janus Henderson Group PLC now owns 1,612,781 shares of the company’s stock valued at $52,456,000 after purchasing an additional 161,848 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new position in Stoke Therapeutics in the second quarter valued at approximately $959,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genetic medicines for severe diseases caused by insufficient protein production. The company uses its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to design antisense oligonucleotides that can increase the expression of specific genes and potentially address the underlying causes of genetic disorders.

Stoke’s leading product candidate is STK-001, an investigational antisense oligonucleotide being developed for the treatment of Dravet syndrome, a severe genetic epilepsy most commonly associated with mutations in the SCN1A gene.